
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
15 June 2018
Nick Boles’ Ambulatory Care Unit opening speech
An edited extract of the speech Nick Boles MP made at the official opening of the Leukaemia UK Ambulatory Care Unit.
19 February 2024
Leukaemia UK launches new Patient Care Pioneer Award funding initiative
Leukaemia UK is delighted to launch a brand-new funding scheme in 2024, intended specifically for innovative, patient-focussed applied research and targeting UK-based healthcare professionals. The first of its kind for…
8 November 2022
Leukaemia UK announces John Goldman Fellows for 2022
Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…
9 November 2017
Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’
We are a leading charity making a difference to families affected by leukaemia, lymphoma, myeloma and other blood cancers.